Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 15, 2023
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 12, 2023
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights May 12, 2023
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy May 11, 2023
Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call May 11, 2023
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023 May 04, 2023
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H Apr 24, 2023
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol Apr 17, 2023
